Industry Overview - The MedTech sector is navigating a global economy characterized by slowing growth, moderating inflation, and heightened geopolitical uncertainty, impacting healthcare spending and capital allocation decisions [1][2] - Despite challenges such as higher input costs and labor shortages, demand for advanced medical technologies remains steady due to the sector's essential nature and long-term innovation cycle [1][2] Economic Outlook - The IMF forecasts gradual deceleration of global growth through 2026, with advanced economies growing slower than emerging markets, while global inflation is expected to ease unevenly across regions [2] - Slower economic growth may constrain healthcare budgets, but moderating inflation and improved financial conditions could alleviate cost pressures and stabilize procurement trends [2][3] Future Projections - By 2026, the MedTech sector is anticipated to benefit from a more stable macro environment if inflation continues to decline and financing conditions remain favorable [3] - Demand is expected to favor technologies that enhance efficiency, outpatient care, and automation, positioning strong MedTech companies for better performance in a slower-growth economy [3] Investment Considerations - Investors may need to reassess MedTech companies that have seen significant gains but could face challenges in 2026 due to selective hospital spending and increased competition [4][9] - Companies like Globus Medical, TransMedics, and Hims & Hers have experienced strong growth driven by innovation, but sustaining this momentum may be difficult as macro conditions normalize [4][8][9] Company Highlights - **Globus Medical (GMED)**: Reported solid growth in Q3 2025, with a projected EPS and revenue increase of 3.9% and 7.9% respectively for 2026. The stock gained 3.8% over the past year [10][11] - **TransMedics (TMDX)**: Announced strong Q3 2025 results and a strategic collaboration for organ transportation. Expected EPS and revenue growth of 2.4% and 20.4% respectively for 2026. The stock surged 101.4% over the past year [12][14] - **Hims & Hers (HIMS)**: Reported strong Q3 2025 results with growth in subscribers and revenue. Projected EPS and revenue growth of 22.3% and 17.6% respectively for 2026. The stock increased by 32.6% over the past year [15][18]

Market Overview - U.S. stock markets have continued to rise in 2025, with the Dow and S&P 500 gaining 0.3% and 0.1% in November, while the Nasdaq Composite fell by 1.5% [1][2] - Year-to-date performance shows the Dow, S&P 500, and Nasdaq Composite up by 12.6%, 16.7%, and 21.2%, respectively, with expectations of continued growth in December due to a potential interest rate cut by the Fed [3] Investment Opportunities - Recommended stocks for December include Expedia Group Inc. (EXPE), The Allstate Corp. (ALL), Dillard's Inc. (DDS), Kinross Gold Corp. (KGC), and Globus Medical Inc. (GMED), all carrying a Zacks Rank 1 (Strong Buy) and a Zacks Momentum Score of A [4][9] Company Highlights Expedia Group Inc. (EXPE) - Benefits from a strong platform model that enhances customer insights and revenue growth, with an expected revenue growth rate of 6.3% and earnings growth rate of 20.8% for next year [7][8] - Strong liquidity, share buybacks, and dividends highlight financial resilience [8] The Allstate Corp. (ALL) - Consistent growth in premiums with a 7.6% year-over-year increase in net premiums earned in the first nine months of 2025 [10][11] - Expected revenue growth rate of 5.7% and a decline in earnings by 14.5% for next year, with share repurchases totaling $805 million in the first nine months of 2025 [12][11] Dillard's Inc. (DDS) - Capturing growth in both brick-and-mortar and e-commerce, with a 1% year-over-year increase in retail sales [13][14] - Expected revenue growth rate of 0.8% and a decline in earnings by 8.2% for next year [16] Kinross Gold Corp. (KGC) - Strong production profile with a focus on organic growth through projects like the Tasiast mine, which has boosted production capacity [17][18] - Expected revenue growth rate of 6.3% and earnings growth rate of 32% for next year [19] Globus Medical Inc. (GMED) - Strengthened position in the musculoskeletal space through acquisitions, with a focus on expanding product offerings [20][21] - Expected revenue growth rate of 7.2% and earnings growth rate of 11.3% for next year [22]

Core Insights - The U.S. equity markets are currently experiencing volatility due to high valuations, sluggish economic signals, and uncertainty regarding the Federal Reserve's future actions, particularly affecting growth and AI-linked stocks [1] Group 1: Stock Selection Strategy - Retail investors face challenges in stock selection amidst market volatility, making traditional stock-picking methods more relevant [2] - Sales growth is emphasized as a more reliable metric for evaluating stocks compared to earnings growth, as it reflects underlying demand and business model durability [3][10] - Sustained sales growth leads to predictable cash flows, allowing companies to reinvest and maintain stability without excessive borrowing [5] Group 2: Screening Parameters for Stocks - Selected stocks should have a 5-Year Historical Sales Growth (%) greater than the industry average and Cash Flow exceeding $500 million [6] - Additional criteria include a Price-to-Sales (P/S) Ratio lower than the industry average, indicating better value for revenue [7] - Positive revisions in sales estimates compared to the industry can trigger stock price increases [7] Group 3: Key Metrics for Evaluation - An operating margin greater than 5% over the last five years indicates effective cost control and sales growth outpacing costs [8] - A Return on Equity (ROE) greater than 5% ensures that sales growth translates into profits, indicating wise spending and profitability [9] - Stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) are expected to outperform in various market conditions [9] Group 4: Recommended Stocks - Take-Two Interactive (TTWO) is projected to have a sales growth rate of 14.8% for fiscal 2026 and holds a Zacks Rank of 1 [11] - Globus Medical (GMED) anticipates a sales growth rate of 14.5% for 2025, also with a Zacks Rank of 1 [12] - Rockwell Automation (ROK) expects a sales increase of 5.8% in fiscal 2026 and has a Zacks Rank of 2 [13] - Canadian Natural Resources (CNQ) forecasts a sales growth of 5.7% for 2025, currently holding a Zacks Rank of 1 [14] - VICI Properties anticipates a sales growth of 4.1% in 2025 and has a Zacks Rank of 2 [15]

Group 1 - Globus Medical (GMED) has reached the buy point of a long, deep cup-with-handle base in above average volume, indicating strong market interest [1] - The stock is on track for four consecutive weeks of gains, reflecting positive momentum in its performance [1] - Globus Medical was added to the IBD Leaderboard Leaders list, highlighting its status as a top-performing stock [1] Group 2 - Medtronic's stock has seen a 36% surge following blowout quarterly earnings, indicating strong performance in the medical products sector [4] - Globus Medical's composite rating has climbed to 96, showcasing its competitive position in the market [4] - The relative strength rating of Globus Medical has improved to 84, suggesting enhanced technical strength [4]

Core Viewpoint - Globus Medical, Inc. (GMED) is showing potential as a strong stock pick due to a recent "golden cross" event, indicating a bullish trend reversal [1][2]. Technical Indicators - A "golden cross" occurs when a stock's short-term moving average (50-day) crosses above its long-term moving average (200-day), suggesting a bullish breakout is likely [2]. - The golden cross pattern consists of three stages: a downtrend followed by a crossover of moving averages, and finally an upward price movement [3]. Performance Metrics - Over the past four weeks, GMED has experienced a significant price increase of 38.1% [4]. - GMED currently holds a 1 (Strong Buy) rating on the Zacks Rank, indicating strong potential for further price appreciation [4]. Earnings Outlook - The earnings outlook for GMED is positive, with four upward revisions in earnings estimates over the past 60 days, and no downward revisions [4]. - The Zacks Consensus Estimate for GMED has also increased, reinforcing the bullish sentiment around the stock [4]. Investment Consideration - Given the technical indicators and positive earnings revisions, GMED should be considered for inclusion on investors' watchlists [6].

Market Overview - U.S. stocks have shown resilience, maintaining a strong upswing despite volatility, with major indexes near record levels supported by robust corporate earnings and investor appetite [1][2] - The end of the government shutdown has alleviated concerns, allowing for a more optimistic outlook on gradual policy easing from the Federal Reserve [2] Investment Strategy - A relative price strength strategy is recommended, focusing on stocks that outperform the market even during pauses, which helps investors align with market leadership [3][4] - Stocks that exceed their industry or benchmark performance should be prioritized for inclusion in investment portfolios, as they are more likely to yield significant returns [5] Stock Screening Criteria - Stocks should demonstrate positive relative price changes over 1, 4, and 12 weeks, outperforming the S&P 500 [8] - The screening highlights five stocks with strong relative price strength amid market gains, including Par Pacific Holdings, AngloGold Ashanti, Globus Medical, Allient Inc., and Sandisk Corporation [8] Company Highlights - **Par Pacific Holdings (PARR)**: Market cap of $2.2 billion, with a 146.2% share gain over the past year and a 112.3% increase in 2025 earnings estimates [11][8] - **AngloGold Ashanti (AU)**: Market cap over $33 billion, with a 220% share gain in the past year and a 162.4% year-over-year growth in 2025 earnings estimates [12][11] - **Globus Medical (GMED)**: Expected EPS growth rate of 14.3%, with a 3.2% share increase in a year and a positive revision in earnings estimates [13][14] - **Allient Inc. (ALNT)**: Market cap nearly $900 million, with a 117.7% share gain in a year and a 5.2% increase in 2025 earnings estimates [15][16] - **Sandisk Corporation (SNDK)**: Market cap of $37.3 billion, with a 422.9% share gain in a year and a 308% growth in fiscal 2026 earnings estimates [17][18]

Core Viewpoint - Growth investors seek stocks with above-average financial growth, but identifying such stocks can be challenging due to associated risks and volatility [1] Group 1: Company Overview - Globus Medical (GMED) is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 15.9%, with projected EPS growth of 18.2% this year, surpassing the industry average of 18.1% [5] Group 2: Financial Metrics - Cash flow growth for Globus Medical is currently at 86.1%, significantly higher than the industry average of -2.4% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 32.6%, compared to the industry average of 6.3% [7] Group 3: Earnings Estimates - There has been a positive trend in earnings estimate revisions for Globus Medical, with the Zacks Consensus Estimate for the current year increasing by 18% over the past month [8] - The combination of a Zacks Rank 1 and a Growth Score of A positions Globus Medical as a potential outperformer for growth investors [10]

Core Insights - Globus Medical's stock surged over 30% in a single November session following strong third-quarter earnings, indicating robust growth potential [1] - The stock is currently forming the right side of a 42-week cup base, suggesting it is a stock to monitor closely for future performance [1] - The company's IBD SmartSelect Composite Rating improved significantly from 67 to 96, reflecting enhanced overall performance metrics [2] Financial Performance - Globus Medical reported accelerating growth in its third-quarter earnings, which contributed to the stock's notable increase [1] - The relative strength rating of Globus Medical has shown improvement, reaching 73, indicating a positive trend in stock performance [4] Market Position - The stock is recognized for its technical strength, having cleared important benchmarks and achieving an 80-plus relative strength rating [4] - The overall outlook for the biotech sector appears to be improving, particularly with new FDA regulations that may benefit companies like Globus Medical [4]

Group 1 - The article discusses the investment potential of Globus Medical (GMED) after a challenging first quarter earnings report, suggesting that the stock deserves renewed backing [1] - The investment group "Value In Corporate Events" focuses on identifying opportunities in major corporate events such as earnings reports, M&A, and IPOs, providing coverage of 10 significant events monthly [1] - The author emphasizes a long position in GMED, indicating confidence in the company's future performance despite previous market pressures [2]

Core Insights - The cannabis sector is attracting investor interest due to growth opportunities despite market volatility, with marijuana penny stocks showing potential for significant upside as conditions improve [1][2] Industry Overview - The cannabis industry is adapting to changing consumer demands, competitive state markets, and evolving regulations, with a focus on financial discipline and strategic progress [2] - State-level expansion continues to support gradual industry growth, even amidst uncertainty regarding federal reform [2] Company Highlights - **Glass House Brands Inc. (GLASF)**: Focuses on large-scale greenhouse cultivation and retail operations in California, emphasizing cost reduction and brand recognition through strategic acquisitions and new store openings [4][7] - **Ascend Wellness Holdings, Inc. (AAWH)**: Operates across multiple states with a diverse product range, balancing pricing pressures and opportunities through geographic diversification and improved customer experiences [8] - **Planet 13 Holdings Inc. (PLNH)**: Known for its experience-based retail model, particularly in Las Vegas, and is expanding into new states while focusing on branded consumer products and operational efficiency [10][12] Financial Performance - **Glass House Brands**: Revenue growth driven by increased production and improved gross margins, with a positive trend in operating income as the company scales production [7] - **Ascend Wellness Holdings**: Revenue growth supported by wholesale and retail expansion, though still facing net losses due to debt and operating expenses; improving margins indicate operational progress [8] - **Planet 13 Holdings**: Modest revenue growth from store expansion, facing pressure on gross profit margins due to operating expenses, but showing progress in reducing overhead costs [12]